ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Driver mutation profiling by next-generation sequencing predicts survival and recurrence after curative-intent resection for pancreatic ductal adenocarcinoma: a genomic cohort study.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNext-generation sequencing (NGS) is standard practice in metastatic pancreatic ductal adenocarcinoma (PDAC), yet its prognostic utility in patients undergoing curative-intent resection remains poorly defined. Characterizing whether driver mutations independently influence post-surgical outcomes [overall survival (OS), time-to-recurrence (TTR), and pathological response (PR)] may inform perioperative risk stratification and patient selection for emerging targeted therapies.
methodsWe conducted a retrospective cohort study of adults undergoing pancreatectomy for PDAC at a single high-volume academic center (2016-2025), with concurrent NGS profiling. Clinicopathologic and genomic data (KRAS, TP53, CDKN2A, SMAD4, and BRCA2 mutations) were obtained from an integrated institutional data commons. OS and TTR were evaluated using Kaplan-Meier analysis and multivariable Cox proportional hazards regression. PR (College of American Pathologists grade 0-1) was assessed using logistic regression.
resultsOf 188 eligible patients (median age: 66; 42.5% female), 83.5% received neoadjuvant chemotherapy and 12.8% achieved major pathological response. KRAS was the most prevalent mutation (84.6%), followed by TP53 (61.7%), CDKN2A (33.0%), SMAD4 (18.1%), and BRCA2 (3.2%). Median TTR and OS were 10.8 and 27.1 months, respectively. In multivariable analysis, TP53 mutation was associated with shorter OS (HR, 1.65 95% CI 1.02-2.66), and CDKN2A mutation with shorter TTR (HR 1.69, 95% CI 1.19-2.39). KRAS was associated with poorer PR compared to wild type (OR 4.45, 95% CI 1.26-15.65).
conclusionIn this exploratory analysis, TP53 and CDKN2A mutations were independently associated with poorer outcomes post-PDAC resection, supporting the potential of upfront NGS for perioperative risk stratification. Prospective, multicenter validation is needed to establish clinical utility.
Indexed as
Identifiers
42870132What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.